Cadrenal Therapeutics reports Q4 2025 results, FDA meeting progress

March 31, 2026 8:45 AM

Cadrenal Therapeutics Inc. (NASDAQ: CVKD) reported fourth quarter 2025 financial results and provided updates on its CAD-1005 program for heparin-induced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found